Related Experiment Video
Updated: Aug 16, 2026

The Rabbit Model of Accelerated Atherosclerosis: A Methodological Perspective of the Iliac Artery Balloon Injury
Published on: October 3, 2017
Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits
Shuji Shakuto1, Kenichi Oshima, Eiko Tsuchiya
1Pharmacology, Lead Optimization, Drug Innovation and Approval Division, Aventis Pharma Ltd., 1-3-2 Minamidai, Kawagoe, Saitama 350-1165, Japan. shuji.shakuto@aventis.com
Aims/Hypothesis:
The purpose of this study was to examine the potential prophylactic effect of glimepiride on experimental atherosclerosis in rabbits and to elucidate the mechanism of action.
Methods:
Rabbits were fed an atherogenic diet containing 1% cholesterol and glimepiride 0.1mg/kg/day for 10 weeks. Plasma lipid levels were determined every 2 weeks. The percentage of atherogenic lesions of thoracic aorta stained with oil red O was calculated and histological examination of the lesions was performed. Lipid and lipid peroxide contents in thoracic aorta and liver were also determined. In addition, the inhibitory effect of glimepiride on human coronary arterial endothelial cell-mediated LDL oxidation was evaluated.
Results:
Accumulation of lipid-laden foam cells in the focal areas of arterial intima was observed in oil red O-positive atherosclerotic lesions. Glimepiride treatment produced significant reduction of atherosclerotic lesions (control, 57.5+/-7.1% versus glimepiride, 20.6+/-4.8%; P<0.01) with no significant change observed in levels of plasma lipids. There were marked decreases in lipid and lipid peroxide contents in the thoracic aorta in glimepiride-treated rabbits with no significant change in levels of liver lipids. In cultured human coronary arterial endothelial cells, glimepiride inhibited oxidative modification of LDL in a dose-dependent manner (IC(50)=8.8 x 10(-7)M) without cytotoxicity.
Conclusions/Interpretation:
These findings suggest that glimepiride prevents the development of aortic atherosclerosis in fat-fed rabbits. The underlying mechanism may be inhibition of endothelial cell-mediated LDL oxidation.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

